Dermatological adverse events are commonly experienced by patients during anticancer treatment [1, 2]. Xerosis is frequently associated with epidermal growth factor receptor inhibitor (EGFRi) or mitogen-activated protein kinase inhibitor (MEKi) treatment [3]. While xerosis is typically mild-to-moderate in intensity, it can significantly impact quality of life [4], especially in patients receiving long-term anticancer therapy.
Impact of Xerosis in Patients with Cancer Receiving Epidermal Growth Factor Receptor or Mitogen-Activated Protein Kinase Inhibitors: ATIXI, A Non-Interventional Prospective Pilot Study
Giampiero Girolomoni
2024-01-01
Abstract
Dermatological adverse events are commonly experienced by patients during anticancer treatment [1, 2]. Xerosis is frequently associated with epidermal growth factor receptor inhibitor (EGFRi) or mitogen-activated protein kinase inhibitor (MEKi) treatment [3]. While xerosis is typically mild-to-moderate in intensity, it can significantly impact quality of life [4], especially in patients receiving long-term anticancer therapy.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Quaglio Derm Pract 2024.pdf
accesso aperto
Licenza:
Dominio pubblico
Dimensione
273.79 kB
Formato
Adobe PDF
|
273.79 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
